Secondary causes of nonalcoholic fatty liver disease
暂无分享,去创建一个
[1] R. Brook,et al. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. , 2010, The American journal of medicine.
[2] G. Langman,et al. Role of non‐alcoholic steatohepatitis in methotrexate‐induced liver injury , 2001, Journal of gastroenterology and hepatology.
[3] T. Forrester,et al. Relation between liver fat content and the rate of VLDL apolipoprotein B-100 synthesis in children with protein-energy malnutrition. , 2005, The American journal of clinical nutrition.
[4] Chris Day,et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.
[5] J. Allard. Other disease associations with non-alcoholic fatty liver disease (NAFLD). , 2002, Best practice & research. Clinical gastroenterology.
[6] B. Burwinkel,et al. Severe Phenotype of Phosphorylase Kinase-Deficient Liver Glycogenosis with Mutations in the PHKG2 Gene , 2003, Pediatric Research.
[7] T. Saphner,et al. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer , 2009, Cancer.
[8] S. Lutsenko,et al. Systems biology approach to Wilson’s disease , 2011, BioMetals.
[9] B. Neuschwander‐Tetri. Nonalcoholic steatohepatitis and the metabolic syndrome. , 2005, The American journal of the medical sciences.
[10] N. Crum‐Cianflone,et al. Nonalcoholic Fatty Liver Disease Among HIV-Infected Persons , 2009, Journal of acquired immune deficiency syndromes.
[11] M. Rao,et al. Conditional ablation of mediator subunit MED1 (MED1/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis. , 2009, Gene expression.
[12] G. Watts,et al. Is adipose tissue lipolysis always an adaptive response to starvation?: implications for non-alcoholic fatty liver disease. , 2008, Clinical science.
[13] F. Farinati,et al. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease. , 2003, The Journal of laboratory and clinical medicine.
[14] W. Chung,et al. Glycogen Storage Disease Type III diagnosis and management guidelines , 2010, Genetics in Medicine.
[15] N. Chalasani,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.
[16] J. Lewis,et al. Drug-induced liver disease. , 1989, The Medical clinics of North America.
[17] R. Coleman,et al. Neutral lipid storage disease: a genetic disorder with abnormalities in the regulation of phospholipid metabolism. , 1998, Journal of lipid research.
[18] A. Tanaka. [Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.
[19] A. Granato,et al. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a , 2002, The Lancet.
[20] C. Thio,et al. Liver disease in the HIV-infected individual. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[21] D. Dhumeaux,et al. Amiodarone‐induced hepatic phospholipidosis: A morphological alteration independent of pseudoalcoholic liver disease , 1988, Hepatology.
[22] E. Dickson,et al. Diagnosis of Wilson's disease presenting as fulminant hepatic failure. , 1983, Gastroenterology.
[23] S. Thung,et al. Hepatic Weber-Christian disease. , 2001, Seminars in liver disease.
[24] M. Rinella,et al. Non-alcoholic fatty liver disease: is bariatric surgery the answer? , 2009, Clinics in liver disease.
[25] G. Assmann,et al. Prevalence of cholesteryl ester storage disease. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[26] M. Swain,et al. Liver abnormalities in celiac disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[27] D. Rader,et al. Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. , 2010, The Journal of clinical investigation.
[28] J H Lewis,et al. Drug-induced liver disease. , 2000, Clinics in liver disease.
[29] Y. Maehara,et al. Recurrent familial hypobetalipoproteinemia–induced nonalcoholic fatty liver disease after living donor liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[30] Andrew J. Brown. Viral hepatitis and fatty liver disease: how an unwelcome guest makes pâté of the host. , 2008, The Biochemical journal.
[31] U. Veronesi,et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial , 2005, BMJ : British Medical Journal.
[32] C. V. D. van der Kallen,et al. Radiological evidence of nonalcoholic fatty liver disease in familial combined hyperlipidemia. , 2004, The American journal of medicine.
[33] J. Ludvigsson,et al. Celiac disease and risk of liver disease: a general population-based study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[34] B. Clary,et al. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. , 2007, Journal of hepatology.
[35] P. Angulo. GI Epidemiology: nonalcoholic fatty liver disease , 2007, Alimentary pharmacology & therapeutics.
[36] C. Day. Non-alcoholic fatty liver disease: a massive problem. , 2011, Clinical medicine.
[37] A. Herneth,et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. , 1997, Gastroenterology.
[38] Satoshi Hirayama,et al. [Familial hypobetalipoproteinemia]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.